Quetiapine

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Depression

Conditions

Depression, Bipolar Disorder

Trial Timeline

Jan 15, 2018 → Mar 19, 2020

About Quetiapine

Quetiapine is a pre-clinical stage product being developed by Astellas Pharma for Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT03403790. Target conditions include Depression, Bipolar Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Depression were approved

Approved (20) Terminated (2) Active (0)
DuloxetineEli LillyApproved
duloxetineEli LillyApproved
DuloxetineEli LillyApproved
DuloxetineEli LillyApproved
DuloxetineEli LillyApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03403790Pre-clinicalCompleted

Competing Products

20 competing products in Depression

See all competitors
ProductCompanyStageHype Score
Olanzapine and Fluoxetine combination (OFC) + FluoxetineEli LillyPhase 3
40
DuloxetineEli LillyApproved
35
FK949EAstellas PharmaPhase 3
40
duloxetine + escitalopram + placeboEli LillyPhase 3
40
duloxetineEli LillyApproved
43
Duloxetine HydrochlorideEli LillyPhase 3
40
DuloxetineEli LillyApproved
43
DuloxetineEli LillyApproved
43
Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)Eli LillyApproved
43
Duloxetine + PlaceboEli LillyPhase 3
40
DuloxetineEli LillyApproved
43
duloxetine + fluoxetine + citalopram + paroxetine + sertralineEli LillyApproved
43
Olanzapine + PlaceboEli LillyPhase 3
40
Olanzapine + Fluoxetine + PlaceboEli LillyPhase 3
32
duloxetine + duloxetineEli LillyPre-clinical
26
olanzapine + ziprasidoneEli LillyApproved
43
Olanzapine Fluoxetine Combination (OFC) + PlaceboEli LillyApproved
43
Drug treatment with CymbaltaEli LillyApproved
39
DuloxetineEli LillyApproved
43
DuloxetineEli LillyApproved
39